These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1371039)

  • 1. Clinical pharmacology: foscarnet.
    Lietman PS
    Am J Med; 1992 Feb; 92(2A):8S-11S. PubMed ID: 1371039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism of action of foscarnet against viral polymerases.
    Crumpacker CS
    Am J Med; 1992 Feb; 92(2A):3S-7S. PubMed ID: 1371038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
    Chrisp P; Clissold SP
    Drugs; 1991 Jan; 41(1):104-29. PubMed ID: 1706982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
    MacGregor RR; Graziani AL; Weiss R; Grunwald JE; Gambertoglio JG
    J Infect Dis; 1991 Oct; 164(4):785-7. PubMed ID: 1654363
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1982; 19(3):387-415. PubMed ID: 6201932
    [No Abstract]   [Full Text] [Related]  

  • 6. Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
    Aweeka F; Gambertoglio J; Mills J; Jacobson MA
    Antimicrob Agents Chemother; 1989 May; 33(5):742-5. PubMed ID: 2546491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
    Jacobson MA; Drew WL; Feinberg J; O'Donnell JJ; Whitmore PV; Miner RD; Parenti D
    J Infect Dis; 1991 Jun; 163(6):1348-51. PubMed ID: 1645385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
    Jacobson MA; Crowe S; Levy J; Aweeka F; Gambertoglio J; McManus N; Mills J
    J Infect Dis; 1988 Oct; 158(4):862-5. PubMed ID: 2844921
    [No Abstract]   [Full Text] [Related]  

  • 9. Foscarnet.
    Med Lett Drugs Ther; 1992 Jan; 34(861):3-4. PubMed ID: 1309469
    [No Abstract]   [Full Text] [Related]  

  • 10. Maintenance therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: foscarnet.
    Jacobson MA
    Am J Med; 1992 Feb; 92(2A):26S-29S. PubMed ID: 1310573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and antiviral properties of sterol phosphonoformates.
    Bailey JM; Lightfoote M; Lillehoj E; Nelson K
    Biochem Soc Trans; 1994 Aug; 22(3):353S. PubMed ID: 7529728
    [No Abstract]   [Full Text] [Related]  

  • 12. Combinations of 3'-azido-3'-deoxythymidine (zidovudine) and phosphonoformate (foscarnet) against human immunodeficiency virus type 1 and cytomegalovirus replication in vitro.
    Eriksson BF; Schinazi RF
    Antimicrob Agents Chemother; 1989 May; 33(5):663-9. PubMed ID: 2546487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
    Polis MA
    Am J Med; 1992 Feb; 92(2A):22S-25S. PubMed ID: 1310572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiviral effects of phosphonoformate (PFA, foscarnet sodium).
    Oberg B
    Pharmacol Ther; 1989; 40(2):213-85. PubMed ID: 2543994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of HIV-1 RNA-dependent DNA polymerase and cellular DNA polymerases alpha, beta and gamma by phosphonoformic acid and other drugs.
    Wondrak EM; Löwer J; Kurth R
    J Antimicrob Chemother; 1988 Feb; 21(2):151-61. PubMed ID: 2452149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.
    Koshida R; Vrang L; Gilljam G; Harmenberg J; Oberg B; Wahren B
    Antimicrob Agents Chemother; 1989 May; 33(5):778-80. PubMed ID: 2526616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foscarnet therapy for AIDS-related opportunistic herpesvirus infections.
    Jacobson MA
    AIDS Clin Rev; 1992; ():173-89. PubMed ID: 1318736
    [No Abstract]   [Full Text] [Related]  

  • 18. Isolation of foscarnet-resistant human cytomegalovirus patterns of resistance and sensitivity to other antiviral drugs.
    Sullivan V; Coen DM
    J Infect Dis; 1991 Oct; 164(4):781-4. PubMed ID: 1654362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.
    Wagstaff AJ; Bryson HM
    Drugs; 1994 Aug; 48(2):199-226. PubMed ID: 7527325
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
    Sjövall J; Bergdahl S; Movin G; Ogenstad S; Saarimäki M
    Antimicrob Agents Chemother; 1989 Jul; 33(7):1023-31. PubMed ID: 2528939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.